30 related articles for article (PubMed ID: 31514019)
1. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.
Roh JW; Huang J; Hu W; Yang X; Jennings NB; Sehgal V; Sohn BH; Han HD; Lee SJ; Thanapprapasr D; Bottsford-Miller J; Zand B; Dalton HJ; Previs RA; Davis AN; Matsuo K; Lee JS; Ram P; Coleman RL; Sood AK
Clin Cancer Res; 2014 May; 20(10):2740-50. PubMed ID: 24634380
[TBL] [Abstract][Full Text] [Related]
2. Identification of a dual TAOK1 and MAP4K5 inhibitor using a structure-based virtual screening approach.
Chao MW; Lin TE; HuangFu WC; Chang CD; Tu HJ; Chen LC; Yen SC; Sung TY; Huang WJ; Yang CR; Pan SL; Hsu KC
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):98-108. PubMed ID: 33167727
[TBL] [Abstract][Full Text] [Related]
3. PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer.
Kikuchi A; Monga SP
Gene Expr; 2015; 16(3):109-27. PubMed ID: 25700367
[TBL] [Abstract][Full Text] [Related]
4. AGO2-RIP-Seq reveals miR-34/miR-449 cluster targetome in sinonasal cancers.
Tomasetti M; Monaco F; Rubini C; Rossato M; De Quattro C; Beltrami C; Sollini G; Pasquini E; Amati M; Goteri G; Santarelli L; Re M
PLoS One; 2024; 19(1):e0295997. PubMed ID: 38215077
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of striatin-4 is associated with poor prognosis in bladder transitional cell carcinoma.
Zhang Y; Gu X; Jiang F; Sun P; Li X
Oncol Lett; 2021 Apr; 21(4):331. PubMed ID: 33692863
[TBL] [Abstract][Full Text] [Related]
6. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
[TBL] [Abstract][Full Text] [Related]
7. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
Gilliland G; Cools J; Stover EH; Wlodarska I; Marynen P
Hematol J; 2004; 5 Suppl 3():S133-7. PubMed ID: 15190295
[No Abstract] [Full Text] [Related]
8. Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1.
Malínková V; Řezníčková E; Jorda R; Gucký T; Kryštof V
Bioorg Med Chem; 2017 Dec; 25(24):6523-6535. PubMed ID: 29089259
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
[TBL] [Abstract][Full Text] [Related]
10. Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome.
Jin Y; Chen Q; Lu Z; Chen B; Pan J
Cancer Sci; 2009 Nov; 100(11):2210-7. PubMed ID: 19671059
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activity evaluation of novel 2,6,9-trisubstituted purine conjugates as potential protein kinases inhibitors.
Vlková K; Gucký T; Peřina M; Řezníčková E; Kryštof V
Bioorg Med Chem Lett; 2022 Mar; 60():128603. PubMed ID: 35124201
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
[TBL] [Abstract][Full Text] [Related]
13. Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity.
Řezníčková E; Gucký T; Kováčová V; Ajani H; Jorda R; Kryštof V
Eur J Med Chem; 2019 Nov; 182():111663. PubMed ID: 31514019
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
